KEY SPEAKERS: Tyrell Norris, Team Leader Cellular Reagents & Assay Development, AstraZeneca PLUS INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP

Size: px

Start display at page:

Download "KEY SPEAKERS: Tyrell Norris, Team Leader Cellular Reagents & Assay Development, AstraZeneca PLUS INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP"

Sharleen Green
5 years ago
Views:

SAVE 300 BOOK BY 19TH JULY AND BOOK BY 30TH SEPTEMBER AND SAVE 100 A well organised conference with some very interesting and good

.. Cell Based Assays The latest in Phenotypic, 3D and Ion Channel based cellular assays Marriott Regents Park Hotel, London, UK

identification of small molecules See how you can implement a primary cell assay plan through a case study of SARdriving assay The

accelerated primary cell screening systems such as those utilised by GSK Hear from over 12 big pharma case study sessions KEY

Boehringer-Ingelheim Xavier Leroy, Director, Actelion Pamela Tranter, Investigator III, Novartis Eric Tang, Associate Principle

Ludbrook, Section Head, GlaxoSmithKline Anthony Davies, Director, Trinity College Dublin Tyrell Norris, Team Leader Cellular

Regents Park London, UK Overcoming the challenges of moving from 2D to 3D Cell based assays in an HCS and HTS environment Hosted

1 SAVE 300 BOOK BY 19TH JULY AND BOOK BY 30TH SEPTEMBER AND SAVE 100 A well organised conference with some very interesting and good talks. Abbott SMi present their 6th annual... Cell Based Assays The latest in Phenotypic, 3D and Ion Channel based cellular assays Marriott Regents Park Hotel, London, UK 18TH - 19TH NOV 2013 WHY ATTEND THIS EVENT: Hear the latest on Phenotypic screening; how target based screening is allowing for identification of small molecules See how you can implement a primary cell assay plan through a case study of SARdriving assay The latest in GPCR and other ion channel targeting pathways and how they are being used in the most recent drug discovery assays Adopt accelerated primary cell screening systems such as those utilised by GSK Hear from over 12 big pharma case study sessions KEY SPEAKERS: Mao Xiang Chen, Biological and Cellular targets, GlaxoSmithKline Martha Brown, Senior Associate Director, Boehringer-Ingelheim Xavier Leroy, Director, Actelion Pamela Tranter, Investigator III, Novartis Eric Tang, Associate Principle Scientist, AstraZeneca Fengrong Zuo, Group Leader of Bioassays, Medimmune Urs Luethi, Senior Lab Head Discovery, Actelion Steve Ludbrook, Section Head, GlaxoSmithKline Anthony Davies, Director, Trinity College Dublin Tyrell Norris, Team Leader Cellular Reagents & Assay Development, AstraZeneca PLUS INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP Wednesday 20th November 2013, Marriott Regents Park London, UK Overcoming the challenges of moving from 2D to 3D Cell based assays in an HCS and HTS environment Hosted by: Anthony Davies, Director, Trinity College Dublin 9.00am pm BOOK BY 19TH JULY AND SAVE 300 / BOOK BY 30TH SEPTEMBER AND SAVE 100 Register online or fax your registration to +44 (0) or call +44 (0)

2 Cell Based Assays Day One Monday 18th November Registration & Coffee 9.00 Chairman's Opening Remarks Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin THE FUTURE OF CELL BASED ASSAYS: PRIMARY PHENOTYPIC ASSAYS 9.10 Expanding the use of primary cell systems in hit identification and compound profiling Current focus on translationally-aligned drug discovery approaches, together with significant technology improvements Several case studies of primary cell systems used at GSK Increased use of phenotypic assays Primary screening activities Steve Ludbrook, Section Head, GlaxoSmithKline 9.50 Phenotypic screening on automated imaging to identify EMT inhibitors Performing phenotypic rather than a target based screen Generating a multiparametric readout based on automated imaging Identifying small molecules that block the EMT (Epithelial-tomesenchyme transition) Case study Urs Luethi, Senior Lab Head Discovery, Actelion Morning Coffee Improving the physiological relevance of SAR-driving assays with primary and stem cells Immortalising cell lines in drug discovery Overview of primary and stem cells in context of SAR-driving assays Case studies Martha Brown, Senior Associate Director, Boehringer-Ingelheim Development of high-throughput recombinant assays for ENaC drug discovery ENaC is an important drug target Robust functional expression of 3 subunits overcoming cellular toxicity Planar array electrophysiology and FLIPR assays HTS and compound profiling Mao Xiang Chen, Biological and Cellular targets, GlaxoSmithKline Networking Lunch 3D CELL CULTURE & FUTURE SCREENING TOOLS FOR PRECLINICAL TOXICOLOGY 1.50 Multi-platform analysis approaches for the evaluation of in 3D biological systems in vitro Practical issues surrounding 3D cell based assays in research Experimental approaches we have under taken to implement a multiplatform analysis of in vitro assays Demonstrate the feasibility of performing assays in an automated screening environment Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin 2.30 Translating drug combinations from in vitro to clinic 2D or 3D cultures? Introductions to 3D culture methods Successful translations from traditional 2D methods AstraZeneca case study Eric Tang, Associate Principle Scientist, AstraZeneca 3.10 Afternoon Tea 3.50 Cell-based Biomarker Assay Platforms in Support of the Clinical Development of Anti-viral Vaccines and mabs at MedImmune Overview of the Cell-based Assay Platforms used for Vaccine Drug Development at MedImmune Development of the Fluorescence-based RSV infectivity and its microneutralization vs MSD-based IgG assays Their utility in phase I clinical study as the immunogenicity biomarkers for the Live Attenuated RSV Vaccine MEDI559 Fengrong Zuo, Principal Scientist, Group Leader Bioassays/Serology, Medimmune Inc 4.20 Using High Content screening to compare 2D Vs 3D cell responses to a panel of chemotherapeutic agents Current Techniques in 3D culture Using 3 Assays (the 3D hanging drop technique, 2D, and stem cell side population) to compare different breast cancer line response to drugs Description of techniques to isolate glioblastoma stem cells from patients Subsequent screening of these lines in 2D Vs 3D and generation of compound fingerprints for each line Gareth Griffiths, Chief Scientific Officer, Imagen Biotech 5.00 Chairman's Closing Remarks and Close of Day One Register online at: Alternatively fa WHO SHOULD ATTEND? Heads of Department, Directors, Managers, Team Leaders, Screening Pre-clinical research Pharmacology Lead discovery technologies Molecular and cellular biology Biological technologies Lead generation and optimisation High content analysis Target identification and validation Target discovery In vitro assays Compound profiling Want to know how you can get involved? Interested in promoting your services to this market? Contact Margaret Mugema, SMi Marketing on +44 (0) , or mmugema@smi-online.co.uk

ssay.co.uk.co.uk Day Two Tuesday 19th November 2013 8.30 Registration & Coffee NOVEL TECHNOLOGIES IN CELL BASED ASSAY PLATFORMS 9.

10 Assay development of multi-subunit ion channels for drug discovery screening using MaxCyte electroporation: GABA-a receptors Assay development for multi-subunit ion channels Scalable transient

50 Luciferase based Complementation assay to dissect GPCR signalling pathways GPCR pathways activation GRKs, Beta-arrestin 2 Endosome, Lysozome, internalization Biased agonists Xavier Leroy,

00 Strategies for screening ion channel drug discovery targets New technologies and applications of automated electrophysiology platforms Approaches for developing Ion channel cell based assays The

3 ssay.co.uk.co.uk Day Two Tuesday 19th November Registration & Coffee NOVEL TECHNOLOGIES IN CELL BASED ASSAY PLATFORMS 9.00 Chairman's Opening Remarks Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin DRUG DESIGN AND TARGETING ION CHANNELS 9.10 Assay development of multi-subunit ion channels for drug discovery screening using MaxCyte electroporation: GABA-a receptors Assay development for multi-subunit ion channels Scalable transient expression using electroporation Comparison of multiple assay platforms Tyrell Norris, Team Leader Cellular Reagents & Assay Development, AstraZeneca 9.50 Luciferase based Complementation assay to dissect GPCR signalling pathways GPCR pathways activation GRKs, Beta-arrestin 2 Endosome, Lysozome, internalization Biased agonists Xavier Leroy, Associate Director, Project Leader, Actelion Morning Coffee Strategies for screening ion channel drug discovery targets New technologies and applications of automated electrophysiology platforms Approaches for developing Ion channel cell based assays The challenges with profiling transient receptor potential (TRP) ion channels Pamela Tranter, Investigator III, Novartis Exploring capabilities of IonWorks Barracuda for ion channel safety profiling in early stage drug discovery Increasing throughput and lowering cost Detecting slow-acting compounds Extending high throughput electrophysiology to Cys-loop transmitter-gated ion channels Optimising assay performance David Standing, Senior Scientist, GlaxoSmithKline 1.50 A new adaptation to the BacMam system Introductions to the BacMam system Recent applications of the study Case study Michiel Van Diepen, Scientist II, Novartis 2.30 FLIM HCA from Automated Multiwell Plate Assays to Live Disease Models Flourescence lifetime imaging (FLIM) Reading protein interactions in automated multiwell plate readers in live dieases models Application of FLIM plate reader to exemplar assay of HIV-Gay protein aggregation with dose response resulting in Z'>0.5 Paul French, Head of Photonics Group, Imperial College London 3.10 Afternoon Tea 3.30 Use of human pluripotent stem cell derivatives as cardiovascular disease models Human embryonic and induced pluripotent stem cells Advantages of high content screening Unique characteristics of cardiomyocyte cultures Development of cardiotoxicity and cell growth assays Sian Harding, Head of Myocardial Function Section, Imperial College London 4.10 Supplying Donated Human Tissue for Cell Based Assays Infrastructure needed to delivery human tissue samples How tissue is used at UCL Industrial collaborators Challenges and solutions to high quality tissue provision Amir Gander, Senior Knowledge Transfer Associate, UCL Medical School Royal Free Campus Networking lunch 5.00 Chairman s Closing Remarks and Close of Day Two x your registration to +44 (0) or call +44 (0) Supported by

4 POST-CONFERENCE WORKSHOP Wednesday 20th November am pm Marriott Regents Park, London, UK Overcoming the challenges of moving from 2D to 3D Cell based assays in an HCS and HTS environment Hosted by: Anthony Davies, Director, Trinity College Dublin Overview of workshop: It is becoming increasingly clear that for many research applications that Three Dimensional (3D) cell culture and cell based assay approaches offer huge advantages over the more conventional 2D cell culture and assay models. This workshop will provide an overview of the very latest 3D cell based assay and culture technologies and techniques for use in biomedical research and drug discovery and the key application areas for these technologies with a focus on HTS and HCS. To gain an insight into the issues surrounding this new area of research The opportunity of discussing issues and ideas and sharing experiences with other scientists Networking opportunities with peer scientists working in the same area Who should attend? Any scientist using or considering the use of 3D cell culture and assay technologies for the first time Registration & Coffee 9.00 Welcome & Introductions 9.10 An overview of the main application areas of 3D assay and cell culture technologies 9.45 An appraisal of all of the currently technologies and their key advantage Morning Refreshments Presentation of research data from a few selected studies using 3D assay technologies Q & A and group discussion Close of Workshop About your wokshop leader: Dr Davies received his PhD in molecular Cardiology from the Faculty of Medicine, University of Dundee Scotland. Following the completion of this research project he joined The Tayside Institute of Child Health, Dundee, Scotland where he focused on the development of specialised cell based assays for the study of hypoxic and ischemic insult in cardiac muscle cells and tissues. Dr Davies undertook further research at the University of Glasgow where he focused on the development of miniaturised cell based assays and cellular arrays for use with high throughput and high content screening. Dr Davies now holds a senior position as director of high content research facility (Trinity HCA) Department of Clinical Medicine Trinity College Dublin where as part of his work has led a research team focused on the development of a novel 3D assay system designed for use in HTS and HCS.

SMi PHARMACEUTICALS FORWARD PLANNER 2013 SEPTEMBER Cancer Vaccines 18 19 September 2013, London Geriatric Safe Medicines Summit 16th September to 17th September 2013 OCTOBER Biosimilars & Biobetters

Pharmaceutical Pricing & Reimbursement 21 22 October 2013, London Point of Care Diagnostics - Market Opportunities and Technology Trents 23 24 October 2013, London NOVEMBER Cell Based Assays 18 19

5 SMi PHARMACEUTICALS FORWARD PLANNER 2013 SEPTEMBER Cancer Vaccines September 2013, London Geriatric Safe Medicines Summit 16th September to 17th September 2013 OCTOBER Biosimilars & Biobetters 1 2 October 2013, London Diabetes 1 2 October 2013, London Orphan Drugs October 2013, London COPD: Novel Therapeutics and Management Strategies October 2013, London European Pharmaceutical Pricing & Reimbursement October 2013, London Point of Care Diagnostics - Market Opportunities and Technology Trents October 2013, London NOVEMBER Cell Based Assays November 2013, London Clinical Trials in CNS November 2013, London DECEMBER Cold Chain Distribution 3 4 December 2013, London JANUARY Pharmaceutical Microbiology January 2014, London Social Media in the Pharmaceutical Industry January 2014, London Quality By Design January 2014, London Pre-Filled Syringes January 2014, London FEBRUARY Parallel Trade February 2014, London Advances and Progress in Drug Design February 2014, London MARCH Superbugs and Superdrugs - A Focus on Antibacterials March 2014, London Imaging in Cancer Drug Development March 2014, London Controlled Release March 2014, London Paediatric Clinical Trials March 2014, London Adaptive Designs SPONSORSHIP March AND 2014, EXHIBITION London OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) or amalick@smi-online.co.uk

6 FAX your booking form to +44 (0) PHONE on +44 (0) CELL BASED ASSAYS Conference: Monday 18th & Tuesday 19th November 2013, Marriott Regents Park Hotel, London, UK 4 WAYS TO REGISTER Workshop: Wednesday 20th November 2013, London POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, Great Suffolk Street, London, SE1 0BS, UK EARLY BIRD Book by 19th July to receive a 300 discount off the conference price DISCOUNT Book by 30th September to receive a 100 discount off the conference price Unique Reference Number Our Reference DELEGATE DETAILS LVP-087 Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: Department/Division: Company/Organisation: Company VAT Number: Address: Town/City: Post/Zip Code: Direct Tel: Mobile: Switchboard: Signature: Country: Direct Fax: I agree to be bound by SMi's Terms and Conditions of Booking. ACCOUNTS DEPT Title: Surname: Forename: Address (if different from above): Town/City: Post/Zip Code: Direct Tel: Country: Direct Fax: Date: Terms and Conditions of Booking Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not share a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a 50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or to tell you about other products and services. Unless you tick here we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website quoting the URN as detailed above your address on the attached letter. CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total COMMERCIAL ORGANISATIONS Conference and Workshop VAT Conference only VAT Workshop only VAT PROMOTIONAL LITERATURE DISTRIBUTION Distribution of your company s promotional literature to all conference attendees VAT The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations. VENUE Marriott Regents Park Hotel, 128 King Henry's Road, London, NW3 3ST Please contact me to book my hotel Alternatively call us on +44 (0) , hotels@smi-online.co.uk or fax +44 (0) DOCUMENTATION I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total Access to the conference documentation on the Document Portal VAT The Conference Presentations paper copy (or only 300 if ordered with the Document Portal) PAYMENT Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-087 and the delegate s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: UK BACS Sort Code , Account Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account IBAN GB48 LOYD Cheque We can only accept Sterling cheques drawn on a UK bank. Credit Card Visa MasterCard American Express All credit card payments will be subject to standard credit card charges. Card No: Valid From / Expiry Date / CVV Number 3 digit security on reverse of card, 4 digits for AMEX card Cardholder s Name: Signature: I agree to be bound by SMi's Terms and Conditions of Booking. Card Billing Address (If different from above): VAT Date: VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document Portal and Literature Distribution for all UK customers and for those EU customers not supplying a registration number for their own country here: If you have any further queries please call the Events Team on tel +44 (0) or you can them at events@smi-online.co.uk

PLUS AN INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOP. Tuesday 20th January 2015, Marriott Regents Park Hotel, London, UK

PLUS AN INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOP. Tuesday 20th January 2015, Marriott Regents Park Hotel, London, UK REGISTER BY OCTOBER 31ST AND RECEIVE A 300 DISCOUNT SMi presents the 7th annual conference on Social Media in the Pharmaceutical Industry Reflecting on regulatory insights and customer focus as the vision